DSM Pharmaceuticals Appoints Business Unit Director
DSM Pharmaceuticals appoints a new business unit director of its DSM Biologics/BioSolutions businesses.
DSM Pharmaceuticals has appointed Manja Bouman PhD as president and business unit director of its biopharm businesses at DSM Pharmaceutical Products. Bouman will head the DSM Biologics/BioSolutions businesses within the DSM Pharmaceutical Products business group of Royal DSM. Bouman will report to Lukas Utiger, president and CEO of DSM Pharmaceutical Products, as a member of the management team.
Bouman has a PhD in biochemistry from the State University of New York at Buffalo, School of Medicine & Biomedical Sciences and has held postdoctoral positions there and in Nijmegen, the Netherlands, before joining DSM Gist-Brocades in 1997. In that role, Bouman was responsible for new business development and licensing & technology moving to Kiadis Pharma B.V. as CEO in 2004. Bouman was most recently CEO of Regenesance, a company that focuses on the development of monoclonal antibodies that inhibit MAC formation for treatment of chronic and acute neurological disorders.
Bouman also heads DSM BioSolutions, which offers large-scale fermentation for large-and small-molecule API’s for therapeutic proteins and enzymes at DSM’s Capua, Italy site, with support from the DSM Biotechnology Center in Delft, the Netherlands.
Source: DSM Pharmaceuticals
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
